

## **CLINICAL STUDY REPORT**

### **FULL**

#### **FINAL**

Study Number: 109MS302

**Study Title:** A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Name of Study Treatment: BG00012 (dimethyl fumarate)

Indication: Relapsing-Remitting Multiple Sclerosis

Development Phase: 3

Date of First Treatment: 28 July 2007 End of Study Date: 24 August 2011

Sponsor: Biogen Idec Inc. Biogen Idec Ltd.

14 Cambridge CenterInnovation HouseCambridge, MA 0214270 Norden Road

United States Maidenhead Berkshire SL6 4AY

United Kingdom

Name of Sponsor Signatory: Gilmore O'Neill, MB, MRCPI, MMSc

Vice President, Clinical Research

Phone (617) 914-4725; Fax (617) 679-3518

Sponsor's Study Medical Director: Katherine T. Dawson, MD

Senior Director, Clinical Development, MS Phone (617) 914-6377; Fax (617) 679-3518


Report Date: 14 January 2012

This study was conducted in accordance with the ethical principles of Good Clinical Practice, according to the ICH Harmonized Tripartite Guideline.



## 6. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

**6.1.** Investigators



Investigator meetings and/or site initiation visits were held for the purpose of training the Investigators, examining and treating neurologists, study coordinators, and other team members on the procedures, tests, and evaluations to be used in the study. Investigator meetings occurred in Dublin, Ireland (February and April 2007); Boston, Massachusetts, US (June 2007); Cancun, Mexico (January 2008); Budapest, Hungary (January 2008); and Istanbul, Turkey (November 2008). Training for site personnel who did not attend an Investigator meeting was also provided at site initiation visits that occurred before the start of the study. Additionally, a live meeting webcast for Investigators in the US was held (December 2007), and additional midstudy meetings were held to provide ongoing training to site personnel. Subjects were not enrolled at a given investigational site until after the study staff training had occurred. See Section 9.6 for additional information on training.













### 6.3. Laboratories

The central laboratories contracted to acquire and evaluate MRI scans, analyze clinical laboratory samples, and evaluate electrocardiograms (ECGs) collected in this study are listed in Table 1.

Table 1: Central Laboratories Used in Study 109MS302

Central Laboratory	Responsibilities
	Analysis of clinical samples and sample management. The laboratory manual, documentation of accreditation, and reference ranges are provided in Appendix 16.1.10.
	Evaluation of ECGs collected for this study. The ECG Procedures Manual is provided in Appendix 16.1.10.
	Acquisition and evaluation of MRI scans with and without gadolinium, was performed under the direction of Review Charter and site acquisition guidelines are provided in Appendix 16.1.10. MRI assessments are described in Section 9.5.2.2.

## **6.4.** Contractors and/or Vendors

Contract research organizations and vendors that performed services in this study are listed in Table 2 with their respective responsibilities.



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

